Researchers in Canada have detected a novel oncolytic viral therapy against prostate cancer with use of a virus called the reovirus, according to study results published in Cancer Research, a journal of the American Association for Cancer Research… Read Full Article

Researchers in Canada have detected a novel oncolytic viral therapy against prostate cancer with use of a virus called the reovirus, according to study results published in Cancer Research, a journal of the American Association for Cancer Research… Read Full Article

Millennium: The Takeda Oncology Company today announced the presentation of safety, pharmacokinetic and efficacy data from the Phase I portion of a Phase I/II clinical trial evaluating TAK-700 in patients with metastatic castration resistant prostate cancer (mCRPC)… Read Full Article

Prostate-specific dietary supplements should not be taken during radiation therapy treatments because they have been shown to increase the radiosensitivity of normal prostate cell lines, leading to normal tissue complications, according to a study in the March issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society … Read Full Article

Gen-Probe’s (Nasdaq: GPRO) PROGENSA® PCA3 assay can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy, according to data from the two largest studies to date of the molecular urine test. The studies were presented last week at the American Society of Clinical Oncology’s (ASCO) Genitourinary (GU) Cancers Symposium in San Francisco… Read...

New research published in today’s issue of the Archives of Internal Medicine (Vol. 170, No. 5), by an investigator at The Cancer Institute of New Jersey (CINJ) and colleagues at Memorial Sloan-Kettering Cancer Center in New York, shows that the type of specialist that men with localized prostate cancer see can influence the form of therapy they ultimately receive… Read Full Article

Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, announced the presentation of positive final data, including survival data, from the Company’s Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC)… Read Full Article

Men who undergo prostate-cancer screening should discuss with a doctor the uncertainties, risks and benefits of the test before it is performed, says Edward Partridge, M.D., president-elect of the American Cancer Society (ACS) National Board of Directors and director of the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center… Read Full Article

American Cancer Society issued its new Guideline for the Early Detection of Prostate Cancer. The American Urological Association (AUA), which represents more than 16,000 urologists and urologic health professionals worldwide, issued the following statement in response to the new ACS document. The statement is attributable to AUA President Anton J. Bueschen, MD… Read Full Article

Responding to continued debate over PSA screening, and today’s American Cancer Society statement, the Prostate Cancer Foundation (PCF) reiterated its position that PSA screening remains a valuable tool, in combination with other tools, for identifying potential prostate disease, including cancer… Read Full Article